“…Moreover, CMNC protocol had higher predictability of cell yield concerning the pre-apheresis CD34+ cells [2,4], higher throughput [5] (collection rate of cells per time), and shorter run times with lower and more predictable product volume [2][3][4]. On the other hand, the higher product hematocrit [2] and higher maximal extracorporeal volume (ECV) of CMNC (297 ml) versus one in MNC (191 ml), could be seen as the potential drawbacks, but both disadvantages can be managed relatively easy. According to literature, the RBC in product never exceeded 20 ml 2 , which is suitable even in allogeneic settings and, custom prime with allogeneic blood (BP) of the extracorporeal circuit (ECC) can effectively prevent severe hemodynamic changes.…”